Ãû´Ê½âÊÍ 2>xF){`
|}s*E_/[
1¡¢Í»´¥µçλ£ºÉñ¾µÝÖÊ´ÓÍ»´¥Ç°Ä¤Í¨¹ý°ûÍÂ×÷ÓÃÊÍ·Å£¬¿ç¹ýÍ»´¥¼ä϶£¬×÷ÓÃÓÚÍ»´¥ºóÄ££¬ÔÚµçÉúÀíÑо¿ÉÏ£¬¿ÉÒԹ۲쵽ͻ´¥ºóÄ£ÉÏÒýÆðÒ»¸ö¶ÌÔݵصçλ±ä»¯¡£°üÀ¨EPSPÓëIPSP¡£ w7.V6S$Ga
}_M~2L?i
À©Õ¹£ºÍ»´¥synapse Éñ¾ÔªÓëÉñ¾ÔªÖ®¼äµÄ»úÄÜÁ¬½Óµã¡£ *SbMqASv4G
O~#!l"0 L+
2¡¢Epsp:ÐË·ÜÐÔÍ»´¥ºóµçλ(Excitatory Postsynaptic Potential,EPSP)ÊǵÝÖÊÒýÆðµÄÍ»´¥ºóĤµÄ¶ÌÔÝÈ¥¼«»¯¡£EPSPÊÇÓɶÔNa+ºÍK+¶¼Í¨Í¸µÄ¹È°±ËáÃÅ¿ØÀë×ÓͨµÀ¿ª·ÅËùÐγɡ£ Jy`
B!S_l
%A9NB!
¹È°±ËáÃÅ¿ØÀë×ÓͨµÀ½éµ¼Á½ÖÖ²»Í¬Ê±³ÌµÄEPSC(ExcitatoryPostsynaptic Current) wtQ++l%{G
ul6]!Iy
AMPA/KAÊÜÌåͨµÀ½éµ¼¿ìʱ³ÌµÄEPSC .LnGL]/
;s = l52
NMDAÊÜÌåͨµÀ½éµ¼Âýʱ³ÌµÄEPSC hc(#{]].
T"}5}6rSG
IPSP:ÒÖÖÆÐÔÍ»´¥ºóµçλ(Inhibitory Postsynaptic Potential,IPSP)ÊǵÝÖÊÒýÆðµÄÍ»´¥ºóĤµÄ¶ÌÔݳ¬¼«»¯. 7?!d^$B
(&Kk7<#`
IPSPÊÇÓɶÔCl-ͨ͸µÄGABAºÍGlycineÃÅ¿ØÀë×ÓͨµÀ¿ª·ÅËùÐγɡ£ F`9xVnK=
}#RakV4
3¡¢SynapseÍ»´¥£ºµçÍ»´¥(Electrical Synapse)ºÍ»¯Ñ§ÐÔÍ»´¥(Chemical Synapse)£¬µ«ÒÔ»¯Ñ§ÐÔÍ»´¥ÎªÖ÷¡£µçÍ»´¥Í¨¹ý·ì϶Á¬½Ó(gapjunction)Ö±½ÓÍê³Éϸ°û¼äµÄµçÐÅÏ¢´«µÝ¡£»¯Ñ§ÐÔÍ»´¥´«µÝ±ØÐëÒÀÀµÓÚÉñ¾µÝÖÊ(Neurotransmitters)»òÉñ¾ëÄ(Neuropeptides)×÷ÓÃÓÚÍ»´¥ºóĤµÄÊÜÌå¶øÍê³Éϸ°û¼äµÄÐÅÏ¢´«µÝ¡£ iJ)_RSFK
4¡¢Action potential¶¯×÷µçλ£ºÊÇ´¦ÓÚ¾²Ï¢µçλ״̬µÄϸ°ûĤÊܵ½Êʵ±´Ì¼¤¶ø²úÉúµÄ£¬Ë²¼äʹ°ûÄÚµçλÏà¶ÔÓÚ°ûÍâΪÕýµçλ¡£ÊÇÒ»´Î¿ÉÄæµÄ¡¢¿É´«µ¼µÄµçλ±ä»¯ Gi|w}j
_
!OhC/f(GBZ
Àë×Ó»ù´¡£ºµçѹÃÅ¿ØÄÆÍ¨µÀ½á¹¹ ^qvZXb
GE:vp>>}`
Ó°Ï춯×÷µçλ´«µ¼µÄÒòËØ£ºÖáÍ»´Öϸ£»ÖáÍ»ÉÏÄÆÍ¨µÀµÄÃܶȣ»ËèÇʺÍÌøÔ¾´«µ¼¡£ ONB{_X?
[:
n'k
¶¯×÷µçλËù¾ßÓеÄÌØÐÔµÄÒâÒå:ÏÞÖÆ´«µ¼ÆµÂÊ;²»»á·¢ÉúÖØµþ×ܺÍ;²»»áÔÚϸ°û±íÃæÀ´»ØÍù¸´Õñµ´¡£ xC?6v'
T$)^
gHS
Resting potential¾²Ï¢µçλ£ºÉñ¾ÔªÎ´Êܴ̼¤Ê±´æÔÚÓÚϸ°ûĤÄÚÍâÁ½²àµÄµçλ²î¡£ jh?H.;**
5¡¢Electroencephhy-EEGÄÔµçͼ£ºÊǽ«ÄÔϸ°ûµÄ×Ô·¢·Åµç»î¶¯Í¨¹ýµç×Ó·Å´óÆ÷·Å´ó²¢Ãè¼ÇÔÚÖ½ÉϵÄÒ»Öֿ͹ۼǼ´óÄÔ»úÄÜ״̬µÄ¼ì²é·½·¨¡£ÊÇÒ»ÖÖÎÞ´´ÆÀ¼Û·½·¨¡£ > ym,{EHK
U|H=Y"pL
7¡¢Éñ¾µ÷ÖÊ(Neuromodulator) £ºÓÐһЩÉñ¾µ÷½ÚÎï±¾Éí²¢²»Ö±½Ó´¥·¢ËùÖ§Åäϸ°ûµÄ¹¦ÄÜЧӦ£¬Ö»Êǵ÷ÖÆ´«Í³µÝÖʵÄ×÷Óᣠk
{R>
M!siK2
¿ÉΪÉñ¾Ï¸°û¡¢½ºÖÊϸ°û»òÆäËü·ÖÃÚϸ°ûËùÊÍ·Å£¬¶ÔÖ÷µÝÖÊÆðµ÷ÖÆ×÷ÓᣠR"/GQ`^AqA
v|)4ocFK
±¾Éí²»Ö±½Ó¸ºÔð¿çÍ»´¥ÐźŴ«µÝ»ò²»Ö±½ÓÒýÆðЧӦϸ°ûµÄ¹¦Äܸı䣬¶øÊǵ÷½ÚÐÅÏ¢´«µÝµÄЧÂÊ£¬ÔöÇ¿»òÏ÷ÈõµÝÖʵÄЧӦ¡£ B{n,t}z
v ,i%Q$
¼ä½Óµ÷ÖÆÖ÷µÝÖÊÔÚÍ»´¥Ç°Éñ¾Ä©ÉÒµÄÊͷż°Æä»ù´¡»î¶¯Ë®Æ½¡£ W]$w@.oW[
F$y$'Rzu_B
Ó°ÏìÍ»´¥ºóЧӦϸ°û¶ÔµÝÖʵķ´Ó¦ÐÔ£¬¶ÔµÝÖʵÄЧӦÆðµ÷ÖÆ×÷Óᣠ<`8n^m*
P1.[
8¡¢ÀÄÓÃ(Abuse)Ö¸Ò»ÖÖ·ÇÒ½ÁÆËùÐèµÄ²»Á¼ÓÃÒ©·½Ê½£¬ÓÉÓÚ·´¸´Ê¹ÓÃÒ©Îïµ¼ÖÂÁËÃ÷ÏԵIJ»Á¼ºó¹û£¬Èç²»ÄÜÍê³ÉÖØÒªµÄ¹¤×÷¡¢Ñ§Òµ£¬Ëðº¦ÁËÇûÌå¡¢ÐÄÀí½¡¿µ£¬µ¼Ö·¨ÂÉÉϵÄÎÊÌâµÈ¡£ 6%\J"AgXO
Y,qI@n<
9¡¢ÄÍÊÜÐÔ(Tolerance)Ö¸Ò©ÎïʹÓÃÕß±ØÐëÔö¼Ó¼ÁÁ¿·½ÄÜ»ñµÃËùÐèµÄЧ¹û£¬ÈçÈÔÒÔÔÀ´µÄ¼ÁÁ¿Ôò´ï²»µ½Ëù×·ÇóµÄЧ¹û¡£ @Myo'{3vF
nUaJz
Pl
10¡¢¶¯»úMotivation£ºÖ¸ÐÐΪÆð¶¯Ç°Éñ¾¸ß¼¶²¿Î»ÄÇÖÖÓëµ¼Ö¸ÃÐÐΪ·¢ÉúÓйصÄ˼ά»î¶¯£¬ÊÇÒâÏò¡¢Çý¶¯µÄ¾ÛºÏ£¬Ëü×îÖÕµ¼ÖÂÐÐΪµÄ³öÏÖ¡£ ?>9/#Nv
6$hQ35
11¡¢½ä¶Ï×ÛºÏÖ¢£¨withdrawal syndrome£© c`)\Pb/O
udK%>
ָֹͣʹÓÃÒ©Îï»ò¼õÉÙʹÓÃÒ©Îïºó»òʹÓÃÞ׿¹¼ÁºóËù³öÏÖµÄÌØÊâµÄÐÄÀíÉúÀí֢״Ⱥ¡£²»Í¬µÄÒ©ÎïËùÖµĽä¶ÏÖ¢×´ÒòÆäÒ©ÀíÌØÐÔ²»Í¬¶øÒ죬һ°ã±íÏÖΪËùʹÓÃÒ©ÎïµÄÒ©Àí×÷ÓÃÏà·´µÄÖ¢×´¡£ÀýÈç±½±û°·ÀàÐ˷ܼÁÒÀÀµ½ä¶Ïºó³öÏÖÎÞÁ¦¡¢Ë¼Ë¯¡¢ÇéÐ÷ÒÖÓôµÈÖ¢×´£»¶ø¾Æ¾«(ÖÐÊàÉñ¾ÏµÍ³ÒÖÖÆ¼Á)ÒÀÀµ½ä¶Ïºó³öÏÖÐË·Ü¡¢²»Ãߣ¬ÉõÖÁñ²ðïÑù·¢×÷µÈ±íÏÖ¡£ ~Py`P'+
\{_q.;}
12¡¢³Éñ«(addiction) d"1]4.c
J/`<!$<c
50Äê´úÊÀ½çÎÀÉú×é֯ר¼ÒίԱ»á½«Ò©Îï³Éȳ¶¨ÒåΪ£º¡°ÓÉÓÚ·´¸´Ê¹ÓÃijÖÖÒ©ÎïËùÒýÆðµÄÒ»ÖÖÖÜÆÚÐÔ»òÂýÐÔÖж¾×´Ì¬£¬¾ßÓÐÒÔÏÂÌØÕ÷£º¢ÙÓÐÒ»ÖÖ²»¿É¿¹¾ÜµÄÁ¦Á¿Ç¿ÖÆÐÔµØÇýʹÈËÃÇʹÓøÃÒ©£¬²¢²»ÔñÊÖ¶ÎÈ¥»ñµÃËü£»¢ÚÓмӴó¼ÁÁ¿µÄÇ÷ÊÆ£»¢Û¶Ô¸ÃÒ©µÄЧӦ²úÉú¾«ÉñÒÀÀµ£¬Ò²¿É²úÉúÇûÌåÒÀÀµ£»¢Ü¶Ô¸öÈ˺ÍÉç»á¶¼²úÉúΣº¦¡£ÓÉÓÚ¡°³Éñ«¡±ÕâÒ»ÊõÓïÓÃ;̫¿í·º£¬ÊÀ½çÎÀÉú×éÖ¯½¨ÒéÓá°ÒÀÀµ¡±À´´úÌæ¡°³Éñ«¡±¡£ 8L=HW G!1
l
K{hVqpt
Growth cone£ºÉñ¾ÔªÖáÍ»ºÍÊ÷Í»Éú³¤µÄÄ©¶Ë±»³ÆÎªÉú³¤×µ¡££¬ÊÇÒ»Öָ߶ÈÄܶ¯µÄϸ°û½á¹¹ÌØ»¯ÐÎʽ£¬³Ê±¡µÄ±âƽĤ״£¬Éì³öһЩϸ³¤µÄ˿״α×ã×÷ΪÆäÑÓÉ첿·Ö---¼¡¶¯µ°°×¡£ +%z>H"J.
(Bb5?fw
Ras»ùÒò£¬ÊÇÒ»ÖÖÔ°©»ùÒò£¬ÊÇÕý³£Ï¸°ûÖи߶ȱ£Êصġ°Ï¸°û»ùÒò¡±¡£ËüÓÉÄæ×ªÂ¼²¡¶¾»î»¯ºó¿ÉÒÔת»¯³ÉÓÐÖ°©ÄÜÁ¦µÄ°©»ùÒò¡£ÔÚÕý³£Ï¸°ûÖÐÓÐ3ÖÖrasÔ°©»ùÒò£¬C-Ha-ras, C-Ki-rasºÍC-N-ras¡£